Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

27 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
SARS-CoV-2 Antibody Dynamics after COVID-19 Vaccination and Infection: A Real-World Cross-Sectional Analysis.
Yorsaeng R, Atsawawaranunt K, Suntronwong N, Kanokudom S, Chansaenroj J, Assawakosri S, Nilyanimit P, Aeemjinda R, Khanarat N, Wongsrisang L, Auphimai C, Vichaiwattana P, Klinfueng S, Thongmee T, Srimuan D, Thatsanathorn T, Sudhinaraset N, Wanlapakorn N, Poovorawan Y. Yorsaeng R, et al. Among authors: srimuan d. Vaccines (Basel). 2023 Jun 30;11(7):1184. doi: 10.3390/vaccines11071184. Vaccines (Basel). 2023. PMID: 37515001 Free PMC article.
Assessing the reactogenicity of Tdap vaccine administered during pregnancy and antibodies to Bordetella pertussis antigens in maternal and cord sera of Thai women.
Wanlapakorn N, Maertens K, Chaithongwongwatthana S, Srimuan D, Suratannon N, Vongpunsawad S, Tran TMP, Hens N, Van Damme P, Locht C, Poovorawan Y, Leuridan E. Wanlapakorn N, et al. Among authors: srimuan d. Vaccine. 2018 Mar 7;36(11):1453-1459. doi: 10.1016/j.vaccine.2018.01.059. Vaccine. 2018. PMID: 29426663
Immunogenicity of a third dose viral-vectored COVID-19 vaccine after receiving two-dose inactivated vaccines in healthy adults.
Yorsaeng R, Suntronwong N, Phowatthanasathian H, Assawakosri S, Kanokudom S, Thongmee T, Vichaiwattana P, Auphimai C, Wongsrisang L, Srimuan D, Thatsanatorn T, Klinfueng S, Sudhinaraset N, Wanlapakorn N, Poovorawan Y. Yorsaeng R, et al. Among authors: srimuan d. Vaccine. 2022 Jan 24;40(3):524-530. doi: 10.1016/j.vaccine.2021.11.083. Epub 2021 Dec 3. Vaccine. 2022. PMID: 34893344 Free PMC article.
Safety and Immunogenicity of the Third Booster Dose with Inactivated, Viral Vector, and mRNA COVID-19 Vaccines in Fully Immunized Healthy Adults with Inactivated Vaccine.
Kanokudom S, Assawakosri S, Suntronwong N, Auphimai C, Nilyanimit P, Vichaiwattana P, Thongmee T, Yorsaeng R, Srimuan D, Thatsanatorn T, Klinfueng S, Sudhinaraset N, Wanlapakorn N, Honsawek S, Poovorawan Y. Kanokudom S, et al. Among authors: srimuan d. Vaccines (Basel). 2022 Jan 6;10(1):86. doi: 10.3390/vaccines10010086. Vaccines (Basel). 2022. PMID: 35062747 Free PMC article.
Safety and immunogenicity of heterologous and homologous inactivated and adenoviral-vectored COVID-19 vaccine regimens in healthy adults: a prospective cohort study.
Wanlapakorn N, Suntronwong N, Phowatthanasathian H, Yorsaeng R, Vichaiwattana P, Thongmee T, Auphimai C, Srimuan D, Thatsanatorn T, Assawakosri S, Kanokudom S, Poovorawan Y. Wanlapakorn N, et al. Among authors: srimuan d. Hum Vaccin Immunother. 2022 Dec 31;18(1):2029111. doi: 10.1080/21645515.2022.2029111. Epub 2022 Feb 24. Hum Vaccin Immunother. 2022. PMID: 35209809 Free PMC article.
Neutralizing Activities Against the Omicron Variant After a Heterologous Booster in Healthy Adults Receiving Two Doses of CoronaVac Vaccination.
Assawakosri S, Kanokudom S, Suntronwong N, Auphimai C, Nilyanimit P, Vichaiwattana P, Thongmee T, Duangchinda T, Chantima W, Pakchotanon P, Srimuan D, Thatsanatorn T, Klinfueng S, Yorsaeng R, Sudhinaraset N, Wanlapakorn N, Mongkolsapaya J, Honsawek S, Poovorawan Y. Assawakosri S, et al. Among authors: srimuan d. J Infect Dis. 2022 Oct 17;226(8):1372-1381. doi: 10.1093/infdis/jiac092. J Infect Dis. 2022. PMID: 35267040
COVID-19 Breakthrough Infection after Inactivated Vaccine Induced Robust Antibody Responses and Cross-Neutralization of SARS-CoV-2 Variants, but Less Immunity against Omicron.
Suntronwong N, Yorsaeng R, Puenpa J, Auphimai C, Thongmee T, Vichaiwattana P, Kanokudom S, Duangchinda T, Chantima W, Pakchotanon P, Assawakosri S, Nilyanimit P, Klinfueng S, Wongsrisang L, Srimuan D, Thatsanatorn T, Sudhinaraset N, Wanlapakorn N, Poovorawan Y. Suntronwong N, et al. Among authors: srimuan d. Vaccines (Basel). 2022 Mar 3;10(3):391. doi: 10.3390/vaccines10030391. Vaccines (Basel). 2022. PMID: 35335023 Free PMC article.
27 results